Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05370898 | Not yet recruiting | Primary Osteoporosis

The Study of Chinese Medicine for the Treatment of Primary Osteoporosis
Sponsor:

Wangjing Hospital, China Academy of Chinese Medical Sciences

Brief Summary:

The purpose of this study is to evaluate the efficacy and possible mechanism of traditional Chinese medicine in the treatment of primary osteoporosis (Kidney Yang Deficiency Syndrome).It is a randomized, placebo-controlled trial.

Condition or disease

Primary Osteoporosis

Intervention/treatment

Caltrate D

Chinese medicine prescription

Placebo

Phase

Not Applicable

Detailed Description:

The subjects are selected according to the inclusion criteria and exclusion criteria. Using the network random system, 120 subjects who meet the research criteria are randomly divided into control group and experimental group, with 60 cases in each group. Patients in treatment group take the granule of traditional Chinese medicine prescription, while the control group take simulate granule of the prescription. Both two groups are under symptomatic treatment. Twice a day, in the morning and evening, 30 minutes after meals.The experimental drugs were provided by the pharmacy department of Wangjing hospital, Chinese Academy of traditional Chinese medicine, and the course of treatment was 3 months.The observation time points were before treatment, 2 weeks after treatment, 1 month after treatment and 3 months after treatment. Visual Analogue Score (VAS), Traditional Chinese Medicine（TCM）syndrome score, SF-12 scale and bone metabolism index were used as observation indexes.At the same time, it is planned to determine EphrinB2, EphB4, Runx2 and VEGF in serum by ELISA. Tele-medicine and information management system is established to help achieve follow-up interviews.Random numbers are generated by SAS 9.4 software. The subjects, caregivers, investigators and outcomes assessors in this study are all blinded.}}

Study Type : Interventional
Estimated Enrollment : 120 participants
Masking : Quadruple
Primary Purpose : Treatment
Official Title : Clinical Study of Bugu Shengsui Decoction for the Treatment of Primary Osteoporosis (Kidney Yang Deficiency Syndrome)
Actual Study Start Date : July 1, 2022
Estimated Primary Completion Date : December 1, 2022
Estimated Study Completion Date : May 1, 2023
Arm Intervention/treatment

Experimental: Traditional Chinese medicine

On the basis of general symptomatic treatment of caltrate D，patients in experimental group use the traditional Chinese medicine application prescription.

Drug: Caltrate D

Drug: Chinese medicine prescription

Placebo Comparator: Comparator: placebo

On the basis of general symptomatic treatment of caltrate D，patients in placebo group use the simulate granule of traditional Chinese medicine application prescription.

Drug: Caltrate D

Drug: Placebo
Ages Eligible for Study: 45 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • It meets the diagnostic criteria of Western medicine for primary osteoporosis. the diagnostic criteria of osteoporosis based on the bone mineral density of central axis (lumbar spine 1-4, femoral neck or total hip) or 1/3 bone mineral density of distal radius measured by DXA is t-value ≤ - 2.5;
  • It meets the syndrome differentiation standard of primary osteoporosis with Kidney Yang Deficiency Syndrome;
  • Female menopause > 2 years and 45 years ≤ age < 80 years, or 50 years ≤ male < 80 years;
  • Visual Analogue Score (VAS) was used to evaluate pain ≥ 4 points;
  • Voluntarily participate in this clinical study and sign the informed consent form.
Exclusion Criteria
  • Osteoporotic fracture has occurred, or t-value > - 2.5;
  • Female premenopausal or menopausal years ≤ 2 years, female age < 45 years or ≥ 80 years, male age < 50 years or ≥ 80 years;
  • VAS pain score < 4;
  • Lumbar fusion or severe degenerative changes hinder the measurement of normal bone mineral density, and there are less than 2 consecutive intact lumbar vertebrae for DXA measurement and evaluation;
  • Patients with malignant tumor, cardiovascular, cerebrovascular, liver disease, kidney disease, hematopoietic system and other serious primary diseases;
  • secondary osteoporosis: diabetes, thyroid disease, Cushing syndrome and other metabolic diseases, rheumatoid arthritis, multiple myeloma, gout, absorption syndrome, systemic lupus erythematosus and other systemic diseases.
  • Use drugs affecting bone metabolism, such as bisphosphonates, glucocorticoids, calcitonin, anticonvulsant drugs, heparin and other drugs within 3 months before signing the informed consent;
  • History of serious mental illness or poor compliance;
  • Allergic constitution, allergy to known components of the drug, allergy to calcium or vitamin D;
  • Those who participated in other clinical trials within 3 months.
  • Rejection Criteria
    • False diagnosis and false inclusion;
    • Not receiving one treatment;
    • During the study, in addition to the study medication, drugs known or likely to affect bone metabolism were used.
    • Shedding Standard
      • The subjects withdrew from the test by themselves;
      • Loss of follow-up;
      • The subject received treatment at least once, and there were serious complications or complications and serious adverse events;
      • Although the test was completed, the dosage of the subject was not within the range of 80%-120% of the dosage that should be taken.
The Study of Chinese Medicine for the Treatment of Primary Osteoporosis

Location Details

Please Choose a site

The Study of Chinese Medicine for the Treatment of Primary Osteoporosis

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

China,

Wangjing Hospital of China Academy of Chinese Medical Sciences

Beijing, China,